ICCM
IceCure Medical LtdNASDAQHealthcare$0.30-0.33%ClosedMarket Cap: $20.6M
As of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
2.43
P/S
6.13
EV/EBITDA
-0.81
DCF Value
$-0.22
FCF Yield
-72.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
36.3%
Operating Margin
-863.5%
Net Margin
-445.6%
ROE
-221.0%
ROA
-108.4%
ROIC
-314.8%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $1.3M | $-4.2M | $-0.06 |
| FY 2025 | $3.4M | $-15.1M | $-0.24 |
| Q3 2025 | $850.0K | $-3.9M | $-0.06 |
| Q2 2025 | $525.0K | $-3.4M | $-0.06 |
Analyst Ratings
View AllHC Wainwright & Co.Buy
2025-10-07HC Wainwright & Co.Buy
2025-08-15HC Wainwright & Co.Buy
2025-05-29Trading Activity
Insider Trades
View AllMalca Yonatandirector:
SellWed Mar 25
Huang Yangdirector
SellWed Mar 25
Huang Yangdirector
SellWed Mar 25
Huang Yangdirector
SellWed Mar 25
Huang Yangdirector
SellWed Mar 25
Latest News
Company Info
Sector
Healthcare
Industry
—
Country
IL
Exchange
NASDAQ
Beta
2.52
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.